ASCO 2018 Conference Review - focus on Melanoma - reviewed by Assoc Prof Victoria Atkinson

In this review:

 4 years after stopping pembrolizumab in ipilimumab-naive advanced melanoma
 5-year survival with pembrolizumab in advanced melanoma
 Survival after CLND in melanoma with positive sentinel node
 Encorafenib + binimetinib vs. vemurafenib or encorafenib in BRAF-mutant melanoma
 Adding epacadostat to pembrolizumab in unresectable or metastatic melanoma
 Adjuvant nivolumab vs. ipilimumab after complete resection of stage III/IV melanoma
 Validation of AJCC melanoma staging system, 8th edition
 A CD122-biased agonist + nivolumab in advanced solid tumours
 Avelumab for metastatic, progressed Merkel cell carcinoma
 Cemiplimab for metastatic cutaneous SCC

Please login below to download this issue (PDF)